Life Scientist > Lab Technology

Employees get a share in biotech

26 April, 2002 by Tanya Hollis

Cash-strapped biotech startups are increasingly rewarding their staff with shares in the company.


Freehills lawyer new VP of global IP group

24 April, 2002 by Iain Scott

Adam Liberman, a partner at law firm Freehills, has been appointed vice-president of the Licensing Executives Society International (LESI), a global intellectual property organisations.


Partnering: try before you buy

24 April, 2002 by Melissa Trudinger

Australian biotechnology companies need to think very carefully about who they partner with, according to Garry Redlich, managing director of Peplin Biotech.


Biotech's natural selectors

24 April, 2002 by Iain Scott

One of the spin-offs of Australia's burgeoning biotech sector is an increasingly competitive recruitment sector.


Australia needs science watchdog: academic

22 April, 2002 by Daniella Goldberg

Australia needs a separate statutory body to investigate scientific fraud and misconduct, according to Sydney University academic Assoc Prof Merilyn Walton.


Lab death prompts CSIRO upgrade

22 April, 2002 by Iain Scott

The tragic death of a CSIRO lab team member in an airlock last December has prompted the organisation to make sweeping changes to its lab equipment and staff procedures.


Stan Yakatan: The paradigm shifter

22 April, 2002 by Tanya Hollis

Stan Yakatan, "US venture capital raising guru" and strategic biotechnology adviser to the Victorian government, sits at a table in The Westin Melbourne's Allegro restaurant surrounded by breakfast, documents and five chairs intermittently filled and vacated biotech movers and shakers.


VC's biotech interest hits new heights

22 April, 2002 by Pete Young

Venture capitalists complain they are finding it ever-tougher to coax fresh funds from investors. Yet paradoxically, the total Australian pool of life science risk capital stands at record levels.


The language of biobusiness

22 April, 2002 by Daniella Goldberg

Spend any time in the biobusiness sector and you learn one thing very quickly: it pays to be bilingual. And not in French or Spanish or Japanese, but in the languages of science and money.


Universities need IP strategy

19 April, 2002 by Melissa Trudinger

More attention needs to be paid to intellectual property, especially in Universities and institutions, is the message from Melbourne patent attorney Dr Neil Ireland.


Ambri scientist appointed to NSW Innovation Council

19 April, 2002 by Daniella Goldberg

Ambri's Dr Bruce Cornell is the new addition to the NSW Innovation Council, after being appointed by the Treasurer and Minister for State Development, Michael Egan.


Singapore biomed is $64 million richer

18 April, 2002 by Iain Scott

Biomedical research projects in Singapore have landed $S62.6 million (nearly $AU64 million) in the first round of a new grant scheme launched by the island nation's Agency for Science, technology and Research (A*Star).


Alchemia makes another deal

18 April, 2002 by Pete Young

Demand by drug discovery companies for carbohydrate chemistry specialist Alchemia's library of novel molecules is increasing. An agreement signed with US biotech CelTor BioSystems this week is the second collaborative pact Alchemia has announced in the past three weeks.


Workshop offers support for start-ups

18 April, 2002 by Daniella Goldberg

Evisense, a Sydney University spin-off, holds the patents for some diagnostic devices that are potentially worth millions. The problem is that its inventor, Dr Richard Appleyard, is not able to work on developing his technologies.


GroPep MD dismissed

18 April, 2002 by Tanya Hollis

GroPep has sacked its managing director because of a difference of opinion over the company's direction.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd